Fast Five Quiz: Breast Cancer Myths

Pavani Chalasani, MD, MPH


April 20, 2021

The Endocrine Society guidelines on hormonal replacement in postmenopausal women advises that the underlying risk for breast cancer must be considered in making clinical decisions for each individual. Nonhormonal therapies are recommended for women at high or intermediate risk for breast cancer who are considering menopausal hormone therapy to alleviate bothersome vasomotor symptoms. The guidelines recommend against the use of tibolone in women with a history of breast cancer.

Santen and colleagues found that the increased risk for breast cancer associated with hormonal replacement is significantly influenced by the underlying risk for breast cancer that is unique to each patient. Women who take estrogen and progestin have higher risks for heart disease and breast cancer than women who do not take those hormones. Women who take estrogen alone do not face the same risks.

Read more about menopausal hormone replacement therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.